IntelliVue MX550 patient monitors recalled over an alarm activation issue
Philips North America is recalling the IntelliVue Patient Monitor MX550 over a potential issue where the monitors did not alarm.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Scored 3 under the risk-of-harm criterion: a monitor that fails to alarm can leave a patient event unannounced, and no injuries are reported.
Plain-English summary
The Philips IntelliVue Patient Monitor MX550, product number 866066, is being recalled. The device carries UDI-DI 00884838038783 and the action covers all serial numbers.
The recall follows a potential issue where the IntelliVue monitors did not alarm.
The record lists a quantity of 1,913,441 units for the action. Distribution was worldwide, including nationwide in the United States and to a large number of other countries. The FDA has classified the action as Class II.
A patient monitor that does not alarm may leave a change in a patient's condition unannounced to staff. The enforcement record reports no injuries. Facilities should follow Philips' instructions.
The recalled product
- Product
- DULOXETINE (DULOXETINE HYDROCHLORIDE)
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Category
- Medical Device — Patient monitor
- Affected units
- 3,397
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: 240947C
- 240962C
- Exp. Date 04/2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Breckenridge Pharmaceutical, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · DULOXETINE
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighEnovachem duloxetine capsules exceed the nitrosamine acceptable intake limit
FDA (Drugs) · 2026-06-10
- ModerateDuloxetine Delayed-Release Capsules Recalled for Impurity Above Limit
FDA (Drugs) · 2026-05-13
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
Same manufacturer · Breckenridge Pharmaceutical, Inc.
See all →- HighDuloxetine delayed-release capsules recalled over a nitrosamine impurity above FDA limits
FDA (Drugs) · 2025-12-10
- HighDuloxetine capsules recalled over nitrosamine impurity above the safety assessment limit
FDA (Drugs) · 2025-11-05
- HighDuloxetine delayed-release capsules recalled over N-nitroso-duloxetine above interim limit
FDA (Drugs) · 2025-09-17
- HighQuallent duloxetine 60 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-20
Same hazard · alarm failure
See all →- HighFresenius BlueStar Hemodialysis Machines Recalled for Alarm Defects
FDA (Devices) · 2026-09-02
- HighTreatlife smoke and carbon monoxide detectors can fail to alarm
CPSC · 2026-06-25
- SevereAutomated Impella Controllers recalled over alarm, power and purge cassette faults
FDA (Devices) · 2026-06-03
- HighVital Sync remote monitoring may not receive bedside monitor alarms
FDA (Devices) · 2026-03-18
- HighSmoke alarms recalled because they may not sound in time
CPSC · 2026-02-12